ALNYLAM PHARMACEUTICALS, INC. ALNY
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-0.11
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.7B | $313.7M | — | $465.4M | $789.2M |
| 2024 | $2.2B | -$278.2M | — | -$42.6M | $67.1M |
| 2023 | $1.8B | -$440.2M | — | $41.9M | -$220.6M |
| 2022 | $1.0B | -$1.1B | — | -$613.3M | -$158.2M |
| 2021 | $844.3M | -$852.8M | — | -$718.1M | $588.2M |
| 2020 | $492.9M | -$858.3M | — | -$685.3M | $1.0B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| PYOTT DAVID E I | director | 2026-06-01 | Option exercise | 3,830 | — |
| PYOTT DAVID E I | director | 2026-06-01 | Sell | 921 | $297.71 |
| PYOTT DAVID E I | director | 2026-06-01 | Sell | 1,175 | $298.91 |
| PYOTT DAVID E I | director | 2026-06-01 | Sell | 1,222 | $299.87 |
| PYOTT DAVID E I | director | 2026-06-01 | Sell | 495 | $300.72 |
| PYOTT DAVID E I | director | 2026-06-01 | Sell | 17 | $302.65 |
| Sigal Charles Elliott | director | 2026-05-20 | Grant | 671 | — |
| SCHULMAN AMY W | director | 2026-05-20 | Grant | 838 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.11 (distress)
- Working capital / assets 0.52
- Retained earnings / assets -1.35
- EBIT / assets 0.101
- Equity / liabilities 0.189
Source: SEC EDGAR filings · CIK 0001178670 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.